Αποτελέσματα Αναζήτησης
22 Φεβ 2022 · Anthracycline/cyclophosphamide-taxane-containing chemotherapy (AC-T) is the standard of care in the adjuvant treatment of HER2-negative early breast cancer (EBC), but recent studies...
- Metrics
Metrics - The impact of anthracyclines in intermediate and...
- Full Size Image
Full Size Image - The impact of anthracyclines in...
- Full Size Table
Full Size Table - The impact of anthracyclines in...
- Metrics
With pCR as the primary endpoint, the combination of chemotherapy plus dual HER2-targeting agents achieved a pCR rate in breast (ypT0/is) of 45.8%, compared with 29% for trastuzumab and docetaxel, 24% for pertuzumab and docetaxel, and 16.8% for dual HER2 blockade without chemotherapy (P=.0141).
20 Μαΐ 2024 · Evidence supporting unchanged recommendations and sections on cost implications and more are found in the full guideline publication, and apply to this Rapid Update. 1 Additionally, for guideline tools and resources, including a complete summary table, visit www.asco.org/breast-cancer-guidelines.
14 Αυγ 2024 · Neoadjuvant pembrolizumab plus chemotherapy (P + CT) has emerged as a standard of care for stage II-III triple-negative breast cancer (TNBC). However, the best anthracycline-cyclophosphamide...
AC chemotherapy works by stopping the cancer cells from dividing and multiplying, which blocks the growth of the cancer. Different chemotherapy drugs attack cancer cells at different stages of their growth.
Introduction. Adjuvant chemotherapy improves outcomes of operable breast cancer. Since the landmark study of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (1), there has been an ongoing effort to identify better regimens to improve survival and decrease toxicity.
6 Οκτ 2011 · Among patients with HER2-positive tumors measuring 1 cm or less in the greatest diameter, the estimated 5-year rates of disease-free survival were 86% in the group receiving AC-T plus...
